Source:http://linkedlifedata.com/resource/pubmed/id/16374255
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2005-12-23
|
| pubmed:abstractText |
Delayed release budesonide was approved by the FDA for the treatment of mildly to moderately active Crohn's disease involving the ileum and ascending colon. Controlled trials have demonstrated that budesonide is effective in inducing remission and for maintenance of remission, with less frequent steroid side effects than conventional steroids. We sought to determine the benefit of this medication in clinical practice and to identify any non-FDA-approved uses that may warrant further study.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1078-0998
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
29-32
|
| pubmed:meshHeading |
pubmed-meshheading:16374255-Adolescent,
pubmed-meshheading:16374255-Adult,
pubmed-meshheading:16374255-Aged,
pubmed-meshheading:16374255-Aged, 80 and over,
pubmed-meshheading:16374255-Anti-Inflammatory Agents,
pubmed-meshheading:16374255-Budesonide,
pubmed-meshheading:16374255-Female,
pubmed-meshheading:16374255-Humans,
pubmed-meshheading:16374255-Inflammatory Bowel Diseases,
pubmed-meshheading:16374255-Male,
pubmed-meshheading:16374255-Middle Aged,
pubmed-meshheading:16374255-Retrospective Studies,
pubmed-meshheading:16374255-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice.
|
| pubmed:affiliation |
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
|
| pubmed:publicationType |
Journal Article
|